Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1991-3-13
pubmed:abstractText
The crystal structures of the complexes formed between subtilisin Novo and three inhibitors, eglin c, Arg45-eglin c and Lys53-eglin c have been determined using molecular replacement and difference Fourier techniques and refined at 2.4 A, 2.1 A, and 2.4 A resolution, respectively. The mutants Arg45-eglin c and Lys53-eglin c were constructed by site-directed mutagenesis in order to investigate the inhibitory specificity and stability of eglin c. Arg45-eglin became a potent trypsin inhibitor, in contrast to native eglin, which is an elastase inhibitor. This specificity change was rationalized by comparing the structures of Arg45-eglin and basic pancreatic trypsin inhibitor and their interactions with trypsin. The residue Arg53, which participates in a complex network of hydrogen bonds formed between the core and the binding loop of eglin c, was replaced with the shorter basic amino acid lysine in the mutant Lys53-eglin. Two hydrogen bonds with Thr44, located in the binding loop, can no longer be formed but are partially restored by a water molecule bound in the vicinity of Lys53. Eglin c in complexes with both subtilisin Novo and subtilisin Carlsberg was crystallized in two different space groups. Comparison of the complexes showed a rigid body rotation for the eglin c core of 11.5 degrees with respect to the enzyme, probably caused by different intermolecular contacts in both crystal forms.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0022-2836
pubmed:author
pubmed:issnType
Print
pubmed:day
20
pubmed:volume
217
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
353-71
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:1992167-Amino Acid Sequence, pubmed-meshheading:1992167-Binding Sites, pubmed-meshheading:1992167-Computer Graphics, pubmed-meshheading:1992167-Crystallography, pubmed-meshheading:1992167-DNA Mutational Analysis, pubmed-meshheading:1992167-Humans, pubmed-meshheading:1992167-Kinetics, pubmed-meshheading:1992167-Macromolecular Substances, pubmed-meshheading:1992167-Models, Molecular, pubmed-meshheading:1992167-Molecular Sequence Data, pubmed-meshheading:1992167-Motion, pubmed-meshheading:1992167-Pancreatic Elastase, pubmed-meshheading:1992167-Protein Binding, pubmed-meshheading:1992167-Protein Conformation, pubmed-meshheading:1992167-Proteins, pubmed-meshheading:1992167-Recombinant Proteins, pubmed-meshheading:1992167-Serine Proteinase Inhibitors, pubmed-meshheading:1992167-Serpins, pubmed-meshheading:1992167-Structure-Activity Relationship, pubmed-meshheading:1992167-Subtilisins, pubmed-meshheading:1992167-Trypsin Inhibitors
pubmed:year
1991
pubmed:articleTitle
Refined crystal structures of subtilisin novo in complex with wild-type and two mutant eglins. Comparison with other serine proteinase inhibitor complexes.
pubmed:affiliation
Pharmaceutical Division, Ciba-Geigy Ltd., Basel, Switzerland.
pubmed:publicationType
Journal Article